Tatsuo Kanda

Professor

Niigata University Medical and Dental Hospital

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Tatsuo Kanda is a faculty member at Niigata University Medical and Dental Hospital, Japan. His research focuses on hepatology, with recent publications addressing innovative treatments for hepatitis viruses and the implications of immune-related adverse events in cancer therapies. He has contributed significantly to advancing knowledge in the management of liver diseases and the role of combination therapies in hepatocellular carcinoma.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (6)

Naoki Matsumoto

Nihon University School of Medicine

JAPAN

View details

Kenya Kamimura

Niigata University

JAPAN

View details

Hiroaki Okamoto

Professor

Jichi Medical University

JAPAN

View details

Takeshi Yokoo

Niigata University

JAPAN

View details

Hirofumi Kogure

Nihon University School of Medicine

JAPAN

View details

Shuji Terai

Professor and Chairman

Niigata University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tatsuo Kanda

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Successful Retreatment of Glecaprevir‐Pibrentasvir for Hepatitis C Virus Genotype 2a Infection in Patient Whose Cirrhosis Improved From Decompensation to Compensation After Sofosbuvir–Velpatasvir Therapy

Zinc Acetate Inhibits Hepatitis A Virus Replication: Possible Treatment for Patients with Type A Acute-on-Chronic Liver Failure

Thermal Inactivation of Hepatitis E Virus: A Narrative Review

Carbon-Ion Radiotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects: A Narrative Review

Reply to letter to the editor “Comment on: “Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors””

Reply to Letter to Editor “Unresolved heterogeneity in hepatic irAEs: critical limitations in prognostic interpretation for ICI-treated patients”

Reply to Letter to the Editor “Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations”

Combination therapies with immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma with major vascular invasion

Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Narrative Review

Hepatitis A and E Viruses Are Important Agents of Acute Severe Hepatitis in Asia: A Narrative Review

Collaborators (6)

Naoki Matsumoto

Kenya Kamimura

Hiroaki Okamoto

Takeshi Yokoo

Hirofumi Kogure

Shuji Terai

Make your next move.